AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: An analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonaL antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57)

Journal of the American College of Cardiology

Volumn 63, Issue 5, 2014, Pages 430-433

  Desai, Nihar R ^a   Giugliano, Robert P ^a   Zhou, Jing ^a   Kohli, Payal ^b   Somaratne, Ransi ^c   Hoffman, Elaine ^a   Liu, Thomas ^c   Scott, Robert ^c   Wasserman, Scott M ^c   Sabatine, Marc S ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c AMGEN INC   (United States)

Author keywords

cholesterol; LDL; PCSK9; statins

Indexed keywords

ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN B; ASPARTATE AMINOTRANSFERASE; CREATINE KINASE; EVOLOCUMAB; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; SERINE PROTEINASE; UNCLASSIFIED DRUG;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; EDUCATION PROGRAM; ENZYME INHIBITION; GOAL ATTAINMENT; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; NATIONAL CHOLESTEROL EDUCATION PROGRAM ADULT TREATMENT PANEL III; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; ULTRACENTRIFUGATION; UNSPECIFIED SIDE EFFECT;

APOB; APOLIPOPROTEIN B; CAD; CARDIOVASCULAR; CHD; CHOLESTEROL; CORONARY ARTERY DISEASE; CORONARY HEART DISEASE; CV; HDL-C; HIGH-DENSITY LIPOPROTEIN CHOLESTEROL; LDL; LDL-C; LOW-DENSITY LIPOPROTEIN CHOLESTEROL; NATIONAL CHOLESTEROL EDUCATION PROGRAM-ADULT TREATMENT PANEL III; NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY; NCEP-ATP III; NHANES; PCSK9; STATINS; UC; ULN; ULTRACENTRIFUGATION; UPPER LIMIT OF NORMAL;

ADULT; AGED; ANTIBODIES, MONOCLONAL; CHOLESTEROL, LDL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PATIENT EDUCATION AS TOPIC; PROPROTEIN CONVERTASES; SERINE ENDOPEPTIDASES; THROMBOLYTIC THERAPY; TIME FACTORS; TREATMENT OUTCOME;

EID: 84893230270     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2013.09.048     Document Type: Article

References (6)

1. S.M. Grundy, J.I. Cleeman, and C.N. Merz et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines J Am Coll Cardiol 44 2004 720 732
2. E.V. Kuklina, P.W. Yoon, and N.L. Keenan Trends in high levels of low-density lipoprotein cholesterol in the United States, 1999-2006 JAMA 302 2009 2104 2110
3. D.G. Karalis, R.D. Subramanya, S.E. Hessen, L. Liu, and M.F. Victor Achieving optimal lipid goals in patients with coronary artery disease Am J Cardiol 107 2011 886 890
4. R.P. Giugliano, N.R. Desai, and P. Kohli et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study Lancet 380 2012 2007 2017
5. S.D. Wiviott, C.P. Cannon, and D.A. Morrow et al. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy J Am Coll Cardiol 46 2005 1411 1416
6. J.M. McKenney, M.J. Koren, D.J. Kereiakes, C. Hanotin, A.C. Ferrand, and E.A. Stein Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy J Am Coll Cardiol 59 2012 2344 2353